Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01114191 | A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869) | PHASE1 | COMPLETED | 12 | — | — | May 1, 2010 | Feb 1, 2011 | Jul 26, 2011 | 2 | United States |
Blood samples for the PK of ABT-869 and ketoconazole will be collected at designated time points throughout the study.
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ABT-869 | DRUG | 2.5mg \[5 mg days 1, 8 and 12. 17.5 mg on days 13 and after\] |
| ketoconazole | DRUG | 400 mg days 6-11 |
Inclusion Criteria 1. Male or female and age is \>= 18 years. 2. Must have a histologically or cytologically confirmed non-hematologic malignancy. 3. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-2. 4. Must have adequate bone marrow, renal and hepatic function as follows: * B...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |